The association between glenoid component design and revision risk in anatomic total shoulder arthroplasty.


Journal

Journal of shoulder and elbow surgery
ISSN: 1532-6500
Titre abrégé: J Shoulder Elbow Surg
Pays: United States
ID NLM: 9206499

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 12 12 2019
revised: 10 02 2020
accepted: 20 02 2020
pubmed: 9 6 2020
medline: 17 2 2021
entrez: 9 6 2020
Statut: ppublish

Résumé

Anatomic total shoulder arthroplasty (TSA) is a proven treatment for glenohumeral joint osteoarthritis, with superior results compared with hemiarthroplasty. However, glenoid component loosening remains a problem and is one of the most common causes of failure in TSA. Multiple component designs have been developed in an attempt to reduce loosening rates. The purpose of this study was to evaluate risk of revision after anatomic TSA according to the glenoid component design. We conducted a cohort study including patients aged ≥18 years who underwent primary elective TSA for the diagnosis of osteoarthritis between 2010 and 2017. Patients with missing implant information, who received stemless humeral implants, or who received augmented glenoid implants, were excluded. Glenoid component designs used were categorized into 4 mutually exclusive treatment groups: polyethylene central-pegged ingrowth, polyethylene-metal hybrid, polyethylene all-cemented pegged, and polyethylene cemented keeled. Multivariable competing risk regression was used to evaluate the risk of glenoid loosening as a cause-specific revision by the glenoid component design. Of the 5566 TSA included in the final cohort, 39.2% of glenoid implants were polyethylene central-pegged ingrowth, 31.1% were polyethylene-metal hybrid, 26.0% were polyethylene all-cemented pegged, and 3.6% were polyethylene cemented keeled. At 6-year final follow-up, 4.1% of TSA were revised for any cause, and 1.4% for glenoid loosening. Compared with the polyethylene central-pegged ingrowth design, no difference in glenoid loosening revision risk was observed for the polyethylene-metal hybrid design (hazard ratio [HR] = 1.15, 95% confidence interval [CI] = 0.42-3.20). However, both the polyethylene all-cemented pegged (HR = 2.48, 95% CI = 1.08-5.66) and polyethylene cemented keeled (HR = 3.84, 95% CI = 1.13-13.00) designs had higher risks for revision due to glenoid loosening. We observed glenoid component designs to be associated with differential risks in revision due to glenoid loosening with polyethylene all-cemented pegged glenoids and polyethylene cemented keeled glenoids having higher risks when compared with polyethylene central-pegged ingrowth glenoids. Surgeons may want to consider the glenoid component design when performing anatomic TSA.

Identifiants

pubmed: 32507730
pii: S1058-2746(20)30235-4
doi: 10.1016/j.jse.2020.02.024
pii:
doi:

Substances chimiques

Bone Cements 0
Metals 0
Polyethylene 9002-88-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2089-2096

Informations de copyright

Copyright © 2020 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Auteurs

Mark T Dillon (MT)

Department of Orthopaedics, The Permanente Medical Group, Sacramento, CA, USA. Electronic address: Mark.T.Dillon@kp.org.

Priscilla H Chan (PH)

Surgical Outcomes and Analysis, Kaiser Permanente, San Diego, CA, USA.

Heather A Prentice (HA)

Surgical Outcomes and Analysis, Kaiser Permanente, San Diego, CA, USA.

William E Burfeind (WE)

Surgical Outcomes and Analysis, Kaiser Permanente, San Diego, CA, USA.

Edward H Yian (EH)

Department of Orthopaedics, Southern California Permanente Medical Group, Anaheim, CA, USA.

Anshuman Singh (A)

Department of Orthopaedics, Southern California Permanente Medical Group, San Diego, CA, USA.

Elizabeth W Paxton (EW)

Surgical Outcomes and Analysis, Kaiser Permanente, San Diego, CA, USA.

Ronald A Navarro (RA)

Department of Orthopaedics, Southern California Permanente Medical Group, Harbor City, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH